Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:alsoKnownAs |
ixazomib
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XX50
|
| gptkbp:CASNumber |
1072833-77-2
|
| gptkbp:chemicalFormula |
C14H14BCl2N5O2
|
| gptkbp:combines |
gptkb:dexamethasone
gptkb:lenalidomide |
| gptkbp:developedBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:eliminationHalfLife |
9.5 days
|
| gptkbp:firstBook |
oral proteasome inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ninlaro
|
| gptkbp:indication |
relapsed multiple myeloma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
protease inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea peripheral neuropathy thrombocytopenia |
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:Takeda
gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|